Interaction potential of lercanidipine, a new vasoselective dihydropyridine calcium antagonist

Arzneimittel-Forschung/Drug Research

Volumn 52, Issue 3, 2002, Pages 155-161

  Klotz, Ulrich ^a  

^a DR MARGARETE FISCHER BOSCH INSTITUTE OF CLINICAL PHARMACOLOGY   (Germany)

Author keywords

Amlodipine; CYP3A4; Cytochrome P450; Drug interactions; Felodipine; Lercanidipine; Nifedipine; Nitrendipine; P glycoprotein

Indexed keywords

AMLODIPINE; AMPRENAVIR; ANTICONVULSIVE AGENT; CALCIUM ANTAGONIST; CALCIUM CHANNEL; CLARITHROMYCIN; CYTOCHROME P450; DIGOXIN; DIHYDROPYRIDINE DERIVATIVE; ERYTHROMYCIN; FELODIPINE; FLUOXETINE; FLUVOXAMINE; GLYCOPROTEIN P; HYPERICUM PERFORATUM EXTRACT; INDINAVIR; ITRACONAZOLE; KETOCONAZOLE; LERCANIDIPINE; NEFAZODONE; NITRENDIPINE; RIFAMPICIN; RITONAVIR; SAQUINAVIR; SERTRALINE;

DRUG ABSORPTION; DRUG METABOLISM; DRUG TRANSPORT; HUMAN; PHARMACODYNAMICS; POLYPHARMACY; REVIEW; VASODILATATION;

EID: 0036199483     PISSN: 00044172     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-0031-1299873     Document Type: Review

References (38)

1. Clinical pharmacokinetics of lercanidipine
2. Use of in vitro and in vivo data to estimate the likelihood of metabolic pharmacokinetic interactions
3. The growing knowledge of St John's wort (Hypericum perforatum L) drug interactions and their clinical significance
4. Hypertension. Matching the right drug to the right patient in essential hypertension
5. Cytochrome P 4503A. Ontogeny and drug disposition
6. Pharmacokinetic-pharmacodynamic consequences and clinical relevance of cytocrome P4503A4 inhibition
7. Felodipine clinical pharmacokinetics
8. Effect of lercanidipine on CYP2D6 and CYP3A4 activities: In vitro/in vivo correlation
9. P-glycoprotein: A defense mechanism limiting oral bioavailability and CNS accumulation of drugs
10. Pharmacological in vitro studies of the new 1,4-dihydropyridine calcium antagonist lercanidipine
11. Amlodipine. A reappraisal of its pharmacological properties and therapeutic use in cardiovascular disease
12. Lercanidipine: Short plasma half-life, long duration of action: A molecular model to rationalize its pharmacokinetic properties
13. Effect of grapefruit juice on the pharmacokinetics of amlodipine in healthy volunteers
14. Drug-grapefruit juice interactions
15. Clinical pharmacokinetics of vasodilators. Part I
16. Inhibition and induction of cytochrome P450 and the clinical implications
17. The classification of calcium antagonists and their selection in the treatment of hypertension: A reappraisal
18. Seville orange juice - Felodipine interaction: Comparison with dilute grapefruit juice and involvement of furocoumarins
19. Lercanidipine - A review of its use in hypertension
20. Lercanidipine: A novel lipophilic dihydropyridine calcium antagonist with long duration of action and high vascular selectivity
21. Drug interactions with cisapride. Clinical implications
22. Adverse cardiovascular drug interactions
23. Arzneimittelinteraktionen bei der therapie mit CSE-hemmern
24. What lessons can be learnt from withdrawal of mibefradil from the market
25. Calcium antagonists. Drug interactions of clinical significance
26. Monotherapy versus combination therapy as first line treatment of uncomplicated arterial hypertension
27. Increased drug delivery to the brain by P-glycoprotein inhibition
28. Influence of diltiazem on the pharmacokinetics of amlodipine in elderly hypertensive patients
29. Pharmacokinetic interactions with calcium channel antagonists
30. Drug-drug interactions of new active substances: Mibefradil example
31. How to use calcium antagonists in hypertension. Putting the JNC-VI guidelines into practice
32. Pharmacokinetic interactions between felodipine and metoprolol
33. Role of metabolic enzymes and efflux transporters in the absorption of drugs from the small intestine
34. Felodipine. A review on the pharmacology and therapeutic use of the extended release formulation in cardiovascular disorders
35. Antiarrhythmic agents. Drug interactions of clinical significance
36. Effects of the antifungal agents on oxidative drug metabolism. Clinical relevance
37. The gut as a barrier to drug absorption. Combined role of cytochrome P4503A4 and P-glycoprotein